FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

58 letters match. Newest first.

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  3. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk
  4. Fresenius Kabi USA LLC

    FDA warns Fresenius Kabi USA over manufacturing failures for sterile injectables at Melrose Park, including endotoxin contamination and media fill failures.

    High risk
  5. Bentley Laboratories LLC

    Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.

    High risk
  6. Jabil Inc.

    FDA warned Jabil Inc. after an inspection found inadequate investigations of mold and sterility failures at its sterile injectable contract manufacturer.

    High risk
  7. Auriga Research Pvt. Ltd.

    Auriga Research, an Indian contract drug testing lab, failed to keep complete lab records and properly investigate failing test results.

    High risk
  8. Spa De Soleil, Inc.

    FDA cites Spa De Soleil for CGMP violations in OTC topical drugs, including water system failures and missing component identity testing.

    High risk
  9. Huons Co., Ltd.

    FDA cites Huons in South Korea for data integrity and sterility failures in drug manufacturing.

    High risk
  10. Medline Inc

    FDA warned Medline Inc about repeated Bacillus cereus contamination in its drug products and inadequate investigations.

    High risk
  11. CareFusion 213, LLC

    FDA warns CareFusion 213 over inadequate investigations and contamination controls at its El Paso sterile drug plant.

    High risk
  12. UCSF Radiopharmaceutical Facility

    FDA cited UCSF Radiopharmaceutical Facility for inadequate sterility failure investigations and environmental monitoring of sterile drug manufacturing.

    High risk
  13. Medical Products Laboratories, Inc.

    Medical Products Laboratories was cited for manufacturing failures and selling unapproved prescription skin drugs.

    High risk
  14. Cohance Lifesciences Limited

    Cohance Lifesciences, a finished-drug maker, was cited for inadequate investigations and dirty shared equipment that caused cross-contamination.

    High risk
  15. Unipack LLC

    FDA says Unipack LLC released suppositories without adequate out-of-specification investigations, complete lab records, and required USP testing.

    High risk
  16. Cdymax India Pharma Private Limited

    FDA warned Cdymax (India) Pharma that its Bangalore API plant had inadequate out-of-specification investigations and unvalidated test methods, making its APIs adulterated.

    High risk
  17. DermaRite Industries, LLC

    DermaRite failed CGMP and sold unapproved, misbranded OTC topical drugs, FDA says.

    High risk
  18. Scientific Protein Laboratories, LLC

    FDA warns Scientific Protein Laboratories over manufacturing failures in animal-derived APIs, including equipment particles and inadequate investigations.

    High risk
  19. Janssen Vaccines Corp., A Johnson & Johnson Company

    FDA warned Janssen Vaccines over inadequate investigations of stopper complaints and missed regulatory notifications for its injection drug.

    Medium
  20. Somerset Therapeutics Private Limited

    FDA cited Somerset Therapeutics' India plant for CGMP failures tied to a contaminated media fill and aseptic processing risks.

    High risk
  21. Amneal Pharmaceuticals, LLC

    FDA warns Amneal over visible particles in ropivacaine injection and inadequate investigations and endotoxin lab controls.

    High risk
  22. Chromatography Institute of America dba Compounder’s International Analytical Laboratory

    FDA warned Chromatography Institute of America, a Colorado contract drug testing lab, that sterility testing and quality controls violated current good manufacturing practice.

    High risk
  23. Oasis Medical, Inc.

    FDA cites Oasis Medical for current good manufacturing practice violations in sterile ophthalmic drugs, including particulate contamination and unresolved sterility failures.

    High risk
  24. Shiva Analyticals Private Limited

    FDA warned Shiva Analyticals, an Indian contract drug testing lab, that inadequate OOS investigations and data integrity failures adulterated tested drugs.

    High risk
  25. Glenmark Pharmaceuticals Limited

    FDA warns Glenmark over unresolved dissolution failures and inadequate investigations at its Pithampur, India drug plant.

    High risk
  26. CTK OTC Laboratories LLC formerly FMK LABS, Inc.

    CTK OTC Laboratories, formerly FMK Labs, failed to investigate out-of-spec results and validate processes for OTC drugs, including sunscreens.

    High risk
  27. NWL Netherlands Services B.V.

    FDA cites NWL Netherlands drug plant for inadequate microbial investigations, missing component identity testing, and weak lab data controls.

    High risk
  28. Excelvision Fareva

    Excelvision Fareva, a sterile drug manufacturer, was cited for inadequate mold/black-speck complaint investigations and aseptic contamination controls.

    High risk
  29. Empower Clinic Services, LLC dba Empower Pharma

    FDA warns Empower Pharma over sterile drug manufacturing deficiencies, labeling, and unapproved compounded drugs after August 2024 inspection.

    High risk
  30. Chem-Tech, Ltd.

    Chem-Tech, Ltd. lacked adequate investigations and clean equipment for its OTC drug.

    High risk
  31. Sanofi

    FDA warned Sanofi subsidiary Genzyme over manufacturing quality failures at its Framingham, MA API plant.

    High risk
  32. Zydus Lifesciences Limited

    FDA warned Zydus Lifesciences over cross-contamination and glass particles in its injectable drugs, leading to recalls.

    High risk
  33. EyePoint Pharmaceuticals, Inc.

    FDA cited EyePoint Pharmaceuticals in Watertown, MA for manufacturing-quality violations affecting its YUTIQ eye implant, including inadequate investigations and process controls.

    High risk
  34. Eugia Pharma Specialities Limited

    FDA cited Eugia Pharma Specialities for CGMP violations at its India sterile injectable plant, including falsified records and contamination risks.

    High risk
  35. Laboratorio Magnachem International

    FDA cited Laboratorio Magnachem for CGMP failures and unapproved, misbranded Broncochem cough/cold drugs after a 2023 inspection.

    High risk
  36. Sun Pharmaceutical Industries Limited

    FDA cited Sun Pharmaceutical Industries for inadequate cleaning and maintenance at its Dadra drug plant, risking cross-contamination, and for weak investigations.

    High risk
  37. Westwood Laboratories LLC

    FDA warned Westwood Laboratories after an inspection found inadequate investigations, raw material testing, lab controls, and water/cleaning controls for OTC drugs.

    High risk
  38. Seatex, LLC

    Seatex, LLC made OTC hand sanitizer drugs with inadequate current good manufacturing practice (CGMP), including shared equipment with industrial chemicals and missing component testing.

    High risk
  39. Natco Pharma Limited

    FDA warned Natco Pharma of adulterated drugs after finding dirty equipment and weak investigations at an India plant.

    High risk
  40. Cosmetic Specialty Labs, Inc.

    FDA warned Cosmetic Specialty Labs after an inspection found manufacturing failures in OTC drugs and an unlisted product.

    High risk
  41. Cipla Limited

    FDA warned Cipla about unresolved albuterol inhaler delivery complaints and contamination in sterile manufacturing at its Indore site.

    High risk
  42. ALI Pharmaceutical Manufacturing, LLC

    FDA says ALI Pharmaceutical Manufacturing failed to validate and control its porcine thyroid drug substance process, making the drug substance adulterated.

    High risk
  43. Denison Pharmaceuticals, LLC

    Denison Pharmaceuticals was cited for manufacturing quality failures, contamination risks, and unapproved infant/homeopathic drugs.

    High risk
  44. Baxter Healthcare Corporation

    FDA warned Baxter over CGMP violations at its India plant, including inadequate endotoxin and visual inspection investigations for sterile injectables.

    High risk
  45. Medgel Private Limited

    FDA cited Medgel Private Limited, an Indian OTC drug maker, for manufacturing violations including poor investigations and data integrity failures.

    High risk
  46. NeilMed Pharmaceuticals Inc.

    FDA warned NeilMed Pharmaceuticals that its OTC drug manufacturing had current good manufacturing practice violations, including missing glycerin identity testing and dirty equipment.

    High risk
  47. RemedyRepack, Inc.

    RemedyRepack, a drug repackager in Indiana, Pennsylvania, failed CGMP, including cleaning and beta-lactam cross-contamination controls.

    High risk
  48. AG Hair Limited

    FDA warned AG Hair Limited over CGMP failures for hand sanitizer drugs, including inadequate investigations, microbiological controls, and component testing.

    High risk
  49. Legacy Pharmaceutical Packaging LLC

    Legacy Pharmaceutical Packaging, a drug repackager, was cited for CGMP violations and insanitary conditions after foreign tablets and floor-picked tablets were found.

    High risk
  50. Sterling Pharmaceutical Services, LLC

    Sterling Pharmaceutical Services, LLC made sterile ophthalmic drugs with manufacturing violations and marketed unapproved new drugs.

    High risk